Table 1.
Study characteristics of the network analyzed samples.
| Study name | Year | N (Post-treatment) | Mean age | Gender (N Male) | Intervention | Symptom measure(s) |
|---|---|---|---|---|---|---|
| Altenstein-Yamanaka | 2017 | 63 | 39.65 | 29 | CBT | BDI-II |
| Azvedo da Silva | 2017 | 30 | 24.07 | 8 | CBT | HRSD-17 |
| Basu | 2017 | 87 | 35.12 | 73 | Escitalopram | MADRS |
| Bernecker | 2016 | 32 | 45.58 | 10 | CBT | HRSD-17 |
| Carter | 2013 | 37 | 39.11 | 13 | CBT | BDI-II (N = 35), HRSD-17 (N = 36), MADRS (N = 37) |
| Ciusani | 2004 | 10 | 38.6 | 3 | Venlafaxine | MADRS |
| Forman | 2007 | 74 | 29.96 | 10 | CBT | BDI-II |
| Groves | 2015 | 19 | 34.95 | 9 | CBT | MADRS |
| Halaris | 2015 | 19 | 38.74 | 5 | Escitalopram | HRSD-17 |
| Heller | 2013 | 12 | 29.67 | 7 | Venlafaxine | HRSD-17 |
| Huang | 2016 | 48 | N/A | N/A | Escitalopram (N = 30), Mirtazapine (N = 8), Venlafaxine (N = 10) | BDI-II |
| Lenze (IRL-GREY) | 2015 | 392 | 69.01 | 141 | Venlafaxine | MADRS |
| Lopes | 2014 | 16 | 35.56 | 5 | CBT | BDI-II |
| Luty | 2007 | 71 | 36 | 22 | CBT | BDI-II, HRSD-17, MADRS |
| Myung | 2012 | 36 | 66 | 7 | Mirtazapine (N = 29), Venlafaxine (N = 7) | HRSD-17 |
| Nakagawa | 2017 | 39 | 39.53 | 25 | CBT | BDI-II, HRSD-17 |
| Saghafi | 2007 | 171 | 73.02 | 53 | Escitalopram | HRSD-17 |
| Sefarty | 2009 | 64 | 74.22 | 11 | CBT | BDI-II |
| Sirot | 2012 | 31 | 49 | 13 | Mirtazapine | HRSD-17 |
| Soczysnka | 2014 | 17 | 42 | 9 | Escitalopram | HRSD-17 |
| Eddington | 2015 | 22 | N/A | N/A | CBT | BDI-II |
| Osvath | 2007 | 99 | 42.26 | 42 | Mirtazapine | HRSD-17 |
N/A, not available.